Last reviewed · How we verify
NCT05771389
RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis
NA trial testing serum raftlin-1 protein levels in Axial Spondyloarthritis in 119 participants. Completed in 9 July 2023.
9 July 2023
Quick facts
| Lead sponsor | Bezmialem Vakif University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 119 |
| Start date | 21 March 2023 |
| Primary completion | 9 July 2023 |
| Estimated completion | 9 July 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- serum raftlin-1 protein levels
Conditions studied
- Axial Spondyloarthritis — all drugs for Axial Spondyloarthritis →
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Sponsor
Bezmialem Vakif University
Who can join
Adults 18 to 65, any sex, with Axial Spondyloarthritis or Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Unlike other rheumatic diseases, acute phase reactants such as C-reactive protein and erythrocyte sedimentation rate are not diagnostic for patients with Spondyloarthropathies (SpA). Also, it is not possible to monitor disease activity with these tests. On the other hand, HLA-B27 positivity varies between races, and 8% of the normal population is HLA-B27 positive. In this manner, new biomarkers for endorsing the diagnosis and monitoring the disease activity are necessary. Acute phase reactants are not sensitive for diagnosing and assessing disease activity. This may lead to a diagnostic delay of up to 9 years. The investigators hypothesize that Raftlin-1, thought to have a regulatory role in TH17 function and IL-17-mediated immunity, may be a novel biomarker for showing inflammation-related clinical features.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Raftlin - a potential biomarker for axial spondyloarthritis and psoriatic arthritis: An observational study.
Yurdakul OV, Kara M, Ince B, Yildiz C, et al · · 2024 · cited 2× · PMID 38941376 · DOI 10.1097/md.0000000000038770
Verify or expand the search:
- PubMed search for NCT05771389
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Axial Spondyloarthritis
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
- NCT07414823 — Walking Football for Axial Spondyloarthritis · NA · active not recruiting
- NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
Other Bezmialem Vakif University trials
Trials by the same sponsor.
- NCT07369297 — PULP SENSIBILITY AND MASSETER INHIBITORY REFLEX IN DIABETIC POLYNEUROPATHY · not yet recruiting
- NCT07433595 — Association Between Child and Parental Stress and Bruxism in Children Aged 8-11 Years · not yet recruiting
- NCT07443111 — Comparison of Virtual Reality-Based and Routine Preoperative Education on Surgical Anxiety and Salivary Cortisol · NA · not yet recruiting
- NCT07421349 — Comparison of Pulmonary Functions and Respiratory Muscle Strength Between Children With Hearing Impairment and Healthy P · not yet recruiting
- NCT07414615 — Aerobic Training in Lower Extremity Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05771389 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bezmialem Vakif University
- Last refreshed: 11 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05771389.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing